Latest Data
This is a summary of selected data presented at the European Academy of Dermatology and Venereology (EADV) Congress held in Amsterdam, the Netherlands, from 25th–28th September 2024; the 44th Annual Fall Clinical Dermatology Congress (FCDC) held in Las Vegas, Nevada, USA, from 24th–27th October 2024; and the 14th Georg Rajka symposium organised by the International Society of Atopic Dermatitis (ISAD) in Doha, Qatar, from 24th–26th October 2024.
Presenters: April Armstrong,1 Matthias Augustin,2 Andrew Blauvelt,3 Simone Ribero,4 Esther Serra-Baldrich5
1. University of California Los Angeles, USA
2. University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
3. Blauvelt Consulting, LLC, Annapolis, Maryland, USA
4. University of Turin, Italy
5. Universitat Autònoma de Barcelona, Spain
Disclosure: Armstrong has served as a research investigator and/or scientific advisor to AbbVie, Almirall, Arcutis Biotherapeutics, ASLAN, Beiersdorf, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Dermira, EPI, Incyte Corporation, Janssen, LEO Pharma A/S, Eli Lilly, Modmed, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB. Augustin has served as a consultant, lecturer, and researcher and/or has received research grants from companies manufacturing drugs for psoriasis, including AbbVie, Almirall, Amgen, Bayer, Beiersdorf, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Centocor, Dermira, Eli Lilly, Galderma, Genzyme, GlaxoSmithKline, Hexal, Incyte, Janssen, LEO Pharma, Medac, Menlo, MSD, Mylan B.V., Novartis, Pfizer, Regeneron, Sandoz, Sanofi, Stallergenes, Trevi, and UCB. Blauvelt served as a speaker (received honoraria) for Eli Lilly and UCB; served as a scientific adviser (received honoraria) for AbbVie, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Corvus, Dermavant, Eli Lilly and Company, Galderma, GlaxoSmithKline, Immunovant, Incyte, IQVIA, Janssen, Leo, Lipidio, Merck, Novartis, Oruka, Paragon, Pfizer, Regeneron, Sanofi, Spherix Global Insights, Sun Pharma, Syncona, Takeda, UCB, and Union; has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Almirall, Alumis, Amgen, Arcutis, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Galderma, Incyte, Janssen, Leo, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, and UCB; and owns stock in Lipidio and Oruka. Ribero received research grants, personal fees, or nonfinancial support from AbbVie, Almirall, Bristol-Myers Squibb, Galderma, LEO Pharma, Eli Lilly, L’Oreal, Novartis, Pfizer, Pierre Fabre, and Sanofi. Serra-Baldrich has received personal fee payments and travel support from Abbvie, Lilly, Sanofi, Novartis, Pfizer, Galderma, and LEO Pharma.
Acknowledgements: Writing assistance was provided by Nicola Humphry, Nottingham, UK.
Disclaimer The opinions expressed in this article belong solely to the authors of the posters.
This content is intended for healthcare professionals. Prescribing information for tralokinumab can be found here. Adverse events reporting information can be found at the end of this article.
Keywords: Atopic dermatitis (AD), biologic therapy, chronic, eczema, long-term, systemic therapy, tralokinumab.
Citation: EMJ Dermatol. 2025;13[Suppl 2]:2-10. https://doi.org/10.33590/emjdermatol/PRLP5831
Support: The publication of this article was sponsored by LEO Pharma.
This article has now been retracted and a retraction statement has been published.
Retraction: Talokinumab in Moderate-to-Severe Atopic Dermatitis: The Latest Data
This article has now been retracted and a retraction statement has been published. Retraction: Talokinumab in Moderate-to-Severe Atopic Dermatitis: The Latest Data
This article has now been retracted and a retraction statement has been published. Retraction: Talokinumab in Moderate-to-Severe Atopic Dermatitis: The Latest Data
This article has now been retracted and a retraction statement has been published. Retraction: Talokinumab in Moderate-to-Severe Atopic Dermatitis: The Latest Data
This article has now been retracted and a retraction statement has been published. Retraction: Talokinumab in Moderate-to-Severe Atopic Dermatitis: The Latest Data
This article has now been retracted and a retraction statement has been published. Retraction: Talokinumab in Moderate-to-Severe Atopic Dermatitis: The Latest Data
This article has now been retracted and a retraction statement has been published. Retraction: Talokinumab in Moderate-to-Severe Atopic Dermatitis: The Latest Data
This article has now been retracted and a retraction statement has been published. Retraction: Talokinumab in Moderate-to-Severe Atopic Dermatitis: The Latest Data